Welcome to our dedicated page for Marvel Biosciences news (Ticker: MBCOF), a resource for investors and traders seeking the latest updates and insights on Marvel Biosciences stock.
Marvel Biosciences Corp. (OTCQB: MBCOF) generates news primarily around its pre-clinical drug development programs in neurological and neurodevelopmental disorders. Through its subsidiary Marvel Biotechnology Inc., the company focuses on MB-204, a novel fluorinated derivative of the approved anti-Parkinson's drug Istradefylline, which targets the adenosine A2A receptor.
News updates for Marvel often highlight preclinical study results and scientific recognition. The company has reported data showing strong preclinical efficacy of MB-204 in models of autism, Rett syndrome and depression, as well as reductions in tau hyperphosphorylation in an acute Alzheimer's disease study. Marvel also announces invitations to present at major scientific meetings, such as the Alzheimer's Association International Conference and the International Rett Syndrome Foundation Scientific Meeting, where it shares findings on MB-204 in Alzheimer's disease, Rett syndrome and autism spectrum disorder.
Investors and followers can also expect regular coverage of Marvel's capital markets activities. The company issues news releases about non-brokered private placements of units, the terms of common share purchase warrants, and any acceleration of warrant expiry dates triggered by trading price thresholds on the TSX Venture Exchange. Additional corporate news includes grants of deferred share units to directors in lieu of cash fees, with details on vesting and settlement conditions.
This news page provides a centralized view of Marvel Biosciences' scientific progress, financing transactions and corporate developments related to MB-204. Readers interested in the evolution of the company’s pre-clinical pipeline and its engagement with the neurology and neurodevelopmental research community can use this feed to follow key milestones and disclosures over time.
Marvel Biosciences (OTC: MBCOF) awarded 50,001 deferred share units (DSUs) to its three independent directors in lieu of cash directors' fees. The DSUs vest on February 17, 2027, are settled on a director's separation and expire 365 days after separation. The deemed value uses the VWAP $0.15 for February 17, 2026 multiplied by the number of DSUs.
Marvel Biosciences (OTCQB: MBCOF) is receiving advisory services and funding from the NRC IRAP to develop a pediatric-friendly, small-volume liquid formulation of lead compound MB-204 for neurodevelopmental disorders including autism, Rett syndrome, and Fragile X syndrome.
The program will evaluate multiple liquid approaches to identify a stable, reproducible format for oral syringe or feeding-tube delivery, support Canadian R&D partnerships, and generate data to inform future pediatric clinical trials and regulatory engagement.
Marvel Biosciences (OTCQB: MBCOF) announced that the Japan Patent Office granted Japanese Patent No. 2022-554855 for composition of matter and methods of use for MB-204, its lead therapeutic candidate. This is the second major jurisdiction to grant composition-of-matter protection for MB-204, strengthening global IP coverage.
MB-204 is a fluorinated analogue of istradefylline, has improved pharmacokinetics versus the parent compound, completed preclinical toxicology, and showed robust preclinical efficacy in depression and multiple autism models, including Rett syndrome; evaluations in Fragile X models are ongoing.
Marvel Biosciences (MBCOF) announced the award of 35,697 deferred share units (DSUs) to its three independent directors in lieu of cash directors' fees, with all DSUs vesting on October 31, 2026.
Vested DSUs will be settled when a director separates from service and expire 365 days after that separation. The DSUs' deemed value is calculated using the VWAP of $0.21 for the corporation's common shares on the TSX Venture Exchange on October 31, 2025 multiplied by the number of DSUs awarded.
Marvel Biosciences (OTC: MBCOF) announced it is accelerating the expiry of warrants issued in its non‑brokered private placement (5,000,000 units at $0.10 per unit) after the listed VWAP trigger occurred.
Each unit included one common share and one warrant exercisable at $0.15 until July 19, 2026, subject to acceleration if the TSXV VWAP ≥ $0.175 for five consecutive trading days. The Triggering Event occurred as of October 3, 2025 and the Company set November 5, 2025 as the Accelerated Expiry Date. To date 4,300,000 warrants have been exercised and 700,000 remain outstanding. Management highlighted continued progress toward Phase 1 trials.
Marvel Biosciences (OTCQB: MBCOF) has secured a significant patent in China for its lead therapeutic candidate MB-204, a novel fluorinated derivative of Istradefylline. The patent (ZL202180020893.4) covers the compound's composition of matter, which is designed to target autism spectrum disorder and related conditions.
MB-204 has demonstrated enhanced potency, longer duration, and improved tolerability in preclinical studies, showing efficacy in models of autism, Rett syndrome, and depression. The company is preparing to advance the drug candidate into Phase 1 clinical trials, addressing a significant market need with approximately 1 in 36 children diagnosed with autism.
Marvel Biosciences (TSXV: MRVL) has granted 142,987 deferred share units (DSUs) to two directors as compensation in lieu of cash directors' fees. The DSUs are valued at $0.16 per unit based on the Volume Weighted Average Price (VWAP) of Marvel's common shares on the TSX Venture Exchange as of July 31, 2025.
The DSUs will vest on July 31, 2026 and will be settled upon the directors' separation from service, with an expiration period of 365 days after their departure.
Marvel Biosciences (TSXV: MRVL) has successfully closed its non-brokered private placement offering, raising gross proceeds of $1,018,750 through the issuance of 8,150,000 units at $0.125 per unit. Each unit consists of one common share and one purchase warrant.
The warrants allow holders to purchase additional common shares at $0.175 per share within a two-year period. The company included an acceleration clause where the warrant expiry can be brought forward if the stock trades at $0.30 or higher for 10 consecutive trading days, with a 30-day notice period for warrant holders to exercise.
Marvel Biosciences (TSXV: MRVL) has closed the second tranche of its non-brokered private placement, issuing 150,000 Units at $0.125 per Unit for gross proceeds of $18,750. Each Unit consists of one Common Share and one Warrant. The company paid $1,312.50 in finder's fees and issued 10,500 finder's warrants, exercisable at $0.175 per share for two years. The total offering aims to raise up to $1.5 million through 12 million Units. The proceeds will fund drug formulation, toxicology studies, and working capital. The company also corrected its March 28 press release regarding finder's fees and announced the termination of a previously announced private placement from January 7, 2025.
Marvel Biosciences has announced significant results from its preclinical Rett syndrome study comparing MB-204 to Trofinetide. The study revealed that MB-204, administered at 10 mg/kg orally once daily, demonstrated superior and longer-lasting effects compared to Trofinetide (100 mg/kg injected).
Key findings show MB-204 maintained effectiveness for up to three weeks after treatment cessation, significantly outperforming Trofinetide in reversing social behavioral deficiencies. The drug showed remarkable results in multiple behavioral tests, including nose contacts, paw contacts, and following episodes (p<0.0001 vs control).
The research, conducted at the iBraiN Institute, will be presented at the International Rett Syndrome Foundation Scientific Meeting in Boston, June 2025. Scientists noted MB-204's potential as a novel treatment for both Rett syndrome and autism, highlighting its sustained effectiveness without reduction after chronic dosing.